By Mackenzie Tatananni
Eli Lilly said Tuesday that it would offer higher doses of its blockbuster weight-loss drug Zepbound for cheaper to customers paying out of pocket.
The pharmaceutical company is selling the new single-dose vials through its direct-to-consumer website, LillyDirect. Through the self-pay program, qualifying patients can purchase 7.5 mg or 10 mg doses for $499 a month, down from $599 and $699, respectively.
The company also trimmed the price of existing 2.5 mg doses and 5 mg doses to $349 and $499 a month, down from $399 and $549 a month, respectively.
Zepbound, the brand name for tirzepatide, was first approved by the Food and Drug Administration in May 2022 for the treatment of type 2 diabetes. It was subsequently approved for a handful of other uses, most recently to treat obstructive sleep apnea in adults with obesity.
Unlike the single-dose auto injector pens covered by insurance, self-paying patients must draw up the medication from the vials themselves before injecting.
Shares of Eli Lilly were up 1.8% to $897.21 in premarket trading. Peer stocks were also rising, with Johnson & Johnson gaining 0.4%, Merck
Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 25, 2025 07:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.